What should I pay attention to when taking Quizartinib? What are the common precautions when using it?

Quizartinib is a FLT3 inhibitor, mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations, especially in relapsed or refractory cases, showing good therapeutic potential. As a targeted drug, quizartinib has certain efficacy advantages in clinical use, but it also comes with some precautions that need to be paid attention to. Patients should strictly follow the doctor's instructions during medication and monitor side effects reasonably to ensure the safety and efficacy of medication. The following are some common precautions when using Quizartinib.

1. Pay attention to cardiotoxicity and monitorQTinterval prolongation

One of the most common side effects of Quizartinib and one that requires the most vigilance is cardiac toxicity, especially QT interval prolongation. If this phenomenon is not intervened in time, it may cause serious arrhythmia and even be life-threatening. Therefore, before starting Quizartinib, doctors usually ask patients to undergo an electrocardiogram to assess the underlying electrical status of the heart. Regular monitoring of the electrocardiogram is also required during medication, especially more frequently during the first few weeks of treatment.

In addition, if the patient also takes other drugs that may prolong the QT interval, such as certain antibiotics (such as erythromycin), antifungals, psychotropic drugs, etc., the risk of cardiac side effects will also increase. While taking quizartinib, the combined use of such drugs should be avoided as much as possible, or the risks should be strictly assessed under the supervision of a doctor.

2. Electrolyte balance needs to be closely monitored

Electrolyte imbalances, especially low levels of potassium, magnesium, and calcium, can also increase the risk ofQT prolongation. Therefore, during the use of Quizartinib, the electrolyte concentration in the blood needs to be tested regularly and replenished in time based on the test results. If hypokalemia or hypomagnesemia is detected, it should be corrected before continuing medication.

At the same time, patients should pay attention to the intake of foods rich in potassium and magnesium in their diet, such as bananas, spinach, nuts, beans, etc. Of course, this cannot replace necessary medical supplementary measures. Maintaining a good water-electrolyte balance is important to reduce drug side effects and improve treatment tolerance.

3. Liver function and routine blood tests cannot be ignored

Quizatinib is mainly metabolized by the liver in the body, so there is a certain burden on liver function during the medication. Regular detection of liver function indicators (such as ALT, AST, bilirubin, etc.) can help early detection of drug-induced liver injury. If there is a significant increase in liver enzymes or symptoms of jaundice, the doctor must be reported promptly and the drug dose may be suspended or adjusted if necessary.

In addition, quizartinib may affect bone marrow function and cause abnormalities in white blood cell, platelet, or red blood cell counts. Therefore, it is recommended to conduct routine blood tests regularly during medication to monitor the occurrence of bone marrow suppression. Once there is an obvious drop in the blood count, the medication regimen should be adjusted as appropriate.

4. Avoid food and drug interactions

The metabolism of Quizartinib is regulated by the CYP3A4 enzyme. Therefore, patients should avoid eating or taking substances that affect the activity of this enzyme while taking the drug. For example, grapefruit and its juice are known inhibitors of CYP3A4 and may increase the concentration of quizartinib in the body, thereby enhancing the risk of toxicity. On the contrary, some CYP3A4 inducers such as rifampicin may reduce drug concentration and affect efficacy.

In addition, before using any Chinese herbal medicines, nutritional supplements or health products, patients should consult their doctors about potential interactions to avoid additional risks from adding medications on their own.

5. Take medication as directed by your doctor and pay attention to compliance

Quizartinib usually has a clear dosage and treatment schedule. Patients must strictly follow the doctor's prescription and are not allowed to increase or decrease the dosage or stop medication at will. Because drug concentration that is too high can easily induce toxic side effects, while too low a concentration may lead to treatment failure or tumor resistance.

At the same time, if any uncomfortable symptoms occur, such as palpitations, dizziness, fatigue, bleeding tendencies, etc., you should seek medical treatment in time to check whether it is related to the drug. Maintaining good compliance during treatment and cooperating with the monitoring and follow-up arranged by the doctor are the keys to improving the success rate of treatment and reducing complications.

In short, quizartinib, as a new type of FLT3 targeted drug, is of great significance in the treatment of relapsed or refractory acute myeloid leukemia. However, because it may cause cardiotoxicity, electrolyte disorders, liver function damage and other problems, close monitoring is required during use. Patients should undergo regular electrocardiogram, electrolyte, liver function and blood routine tests, and pay attention to diet, drug interactions and compliance with taking medications on time. Proper use of Quizartinib under the guidance of professional doctors can maximize its therapeutic benefits while ensuring safety.

Reference materials:https://go.drugbank.com/drugs/DB12874